Evaluation of Outcomes From Treatment of Benign or Malignant Gastrointestinal Diseases

NCT ID: NCT05115877

Last Updated: 2024-03-27

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 1000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-01-07
• Study Completion Date: 2024-05-17

Brief Summary

This study will be a retrospective, registry study collecting data of patients who were diagnosed with benign or malignant gastrointestinal diseases. Data will be collected from patient's chart retrospectively once the patients have completed proper treatment follow up with physicians' practice.

Detailed Description

It is reported in the literature that the treatment of any gastrointestinal disease process, whether benign or malignant, continues to be a huge challenge. For example, patients with gastrointestinal cancer continue to be diagnosed at an advanced stage with medical and surgical options that are improving in terms of outcome measurements but with much more room for improvement. The goal is to continue to review our treatment outcomes to further improve overall survival, overall symptom control, mortality and morbidity.

The main aim of this study is to evaluate and compare the outcomes from our treatment of benign or malignant gastrointestinal diseases through medical chart review.

There is a need to understand and improve the current diagnosis and treatment algorithm for gastrointestinal pathologies. Continued evaluation and study is imperative to ensure that national guidelines are improving to enhance patient cure and/or recovery.

Conditions

Gastrointestinal Disease

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: RETROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• All patients diagnosed and treated for gastrointestinal diseases, benign or malignant from 2005 to 2030.
• Age ≥18 years

Exclusion Criteria

• Patients that are not diagnosed with or treated for gastrointestinal diseases
• Age <18 years

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Methodist Health System

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dhiresh R Jeyarajah

Role: PRINCIPAL_INVESTIGATOR

Methodist Health System

Locations

Methodist Richardson Medical Center

Richardson, Texas, United States

Countries

United States

Other Identifiers

031.HPB.2020.R

Identifier Type: -

Identifier Source: org_study_id